Dyne Therapeutics (NASDAQ:DYN) Upgraded by Wall Street Zen to “Sell” Rating

Wall Street Zen upgraded shares of Dyne Therapeutics (NASDAQ:DYN) from a strong sell rating to a sell rating in a research note published on Saturday.

Other analysts also recently issued research reports about the company. HC Wainwright dropped their price objective on Dyne Therapeutics from $60.00 to $50.00 and set a “buy” rating on the stock in a research note on Tuesday, March 3rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Dyne Therapeutics in a research note on Monday, April 20th. Evercore set a $33.00 price objective on Dyne Therapeutics in a research note on Friday. Sanford C. Bernstein boosted their price objective on shares of Dyne Therapeutics from $23.00 to $24.00 and gave the company a “market perform” rating in a research report on Wednesday. Finally, Jefferies Financial Group reaffirmed a “buy” rating on shares of Dyne Therapeutics in a research report on Monday, March 9th. Three equities research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $35.00.

Dyne Therapeutics Stock Performance

Shares of Dyne Therapeutics stock opened at $17.29 on Friday. The company has a market capitalization of $2.86 billion, a PE ratio of -5.37 and a beta of 1.08. Dyne Therapeutics has a 12 month low of $8.06 and a 12 month high of $25.00. The company has a current ratio of 19.92, a quick ratio of 22.25 and a debt-to-equity ratio of 0.17. The stock’s fifty day simple moving average is $18.34 and its 200 day simple moving average is $18.63.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings data on Monday, May 11th. The company reported ($0.73) EPS for the quarter, topping the consensus estimate of ($0.77) by $0.04. During the same period last year, the company posted ($1.05) EPS. On average, research analysts predict that Dyne Therapeutics will post -2.99 EPS for the current year.

Insider Buying and Selling at Dyne Therapeutics

In other news, Director Jason P. Rhodes sold 287,956 shares of the company’s stock in a transaction dated Wednesday, April 22nd. The stock was sold at an average price of $19.68, for a total transaction of $5,666,974.08. Following the completion of the transaction, the director directly owned 11,663 shares of the company’s stock, valued at $229,527.84. This represents a 96.11% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 1,559,462 shares of company stock worth $29,814,746 over the last ninety days. 14.14% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. T. Rowe Price Investment Management Inc. boosted its position in shares of Dyne Therapeutics by 523.7% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 17,540,089 shares of the company’s stock worth $343,085,000 after buying an additional 14,727,667 shares during the period. Vanguard Group Inc. boosted its position in shares of Dyne Therapeutics by 14.9% during the fourth quarter. Vanguard Group Inc. now owns 11,215,565 shares of the company’s stock worth $219,376,000 after buying an additional 1,455,151 shares during the period. State Street Corp increased its position in shares of Dyne Therapeutics by 27.0% in the fourth quarter. State Street Corp now owns 6,692,745 shares of the company’s stock valued at $130,910,000 after acquiring an additional 1,423,828 shares during the last quarter. Adage Capital Partners GP L.L.C. increased its position in shares of Dyne Therapeutics by 45.5% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 5,172,000 shares of the company’s stock valued at $101,164,000 after acquiring an additional 1,618,000 shares during the last quarter. Finally, Orbis Allan Gray Ltd acquired a new stake in shares of Dyne Therapeutics in the fourth quarter valued at about $93,926,000. 96.68% of the stock is owned by institutional investors and hedge funds.

More Dyne Therapeutics News

Here are the key news stories impacting Dyne Therapeutics this week:

• Positive Sentiment: HC Wainwright reiterated a Buy rating and $50 price target on Dyne Therapeutics while raising several earnings estimates, suggesting analysts remain confident in the company’s longer-term prospects.
• Positive Sentiment: Lifesci Capital also lifted its earnings forecasts for Dyne Therapeutics across multiple periods, pointing to improved expectations for future results.
• Neutral Sentiment: Dyne Therapeutics’ average brokerage rating remains Moderate Buy, indicating Wall Street sentiment is still constructive overall. Dyne Therapeutics, Inc. (NASDAQ:DYN) Given Average Rating of “Moderate Buy” by Brokerages
• Neutral Sentiment: The company recently reported a quarterly loss that was slightly better than expected, which is supportive but not a major catalyst on its own.
• Negative Sentiment: CEO John Cox, CFO Erick Lucera, and insider Douglas Kerr each sold shares this week. The filings say the sales were tied to tax withholding on equity vesting, but insider selling can still weigh on investor sentiment.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.